Hims & Hers Health Management

Management Kriterienprüfungen 1/4

Hims & Hers Health's CEO ist Andrew Dudum , ernannt in Jan 2017, hat eine Amtszeit von 7.42 Jahren. Die jährliche Gesamtvergütung beträgt $14.40M , bestehend aus 4.2% Gehalt und 95.8% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 9.07% der Aktien des Unternehmens, im Wert von $470.31M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.3 Jahre bzw. 2.5 Jahre.

Wichtige Informationen

Andrew Dudum

Geschäftsführender

US$14.4m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts4.2%
Amtszeit als Geschäftsführer7.4yrs
Eigentum des Geschäftsführers9.1%
Durchschnittliche Amtszeit des Managements2.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder2.5yrs

Jüngste Management Updates

Hims & Hers Health, Inc.'s (NYSE:HIMS) CEO Compensation Is Looking A Bit Stretched At The Moment

May 31
Hims & Hers Health, Inc.'s (NYSE:HIMS) CEO Compensation Is Looking A Bit Stretched At The Moment

Recent updates

Why Investors Shouldn't Be Surprised By Hims & Hers Health, Inc.'s (NYSE:HIMS) 70% Share Price Surge

Jun 19
Why Investors Shouldn't Be Surprised By Hims & Hers Health, Inc.'s (NYSE:HIMS) 70% Share Price Surge

Hims & Hers: The Undervalued Gem Poised For Growth

Jun 18

Beyond The Marketing Machine: Why Hims & Hers Stock Might Be Vulnerable

Jun 10

Hims & Hers Health, Inc.'s (NYSE:HIMS) CEO Compensation Is Looking A Bit Stretched At The Moment

May 31
Hims & Hers Health, Inc.'s (NYSE:HIMS) CEO Compensation Is Looking A Bit Stretched At The Moment

Hims & Hers: Soaring On Access To Compounded GLP-1 Drugs, Further Volatility Ahead

May 21

Hims & Hers Health: An Unforced Error

May 06

Hims & Hers Health, Inc. (NYSE:HIMS) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing

May 04
Hims & Hers Health, Inc. (NYSE:HIMS) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing

Hims & Hers Health: Becoming A Market Leader Within The Growing Digital Health Industry

Apr 24

Hims & Hers Health: Strong Prospects But Weak Business Model Consolidation

Apr 05

Hims & Hers: 5 Reasons Why This Is A Phenomenal Long-Term Growth Stock

Mar 21

Pills Pay The Bills: Mini Deep Dive On Hims & Hers Health

Mar 12

Investors Appear Satisfied With Hims & Hers Health, Inc.'s (NYSE:HIMS) Prospects As Shares Rocket 49%

Feb 28
Investors Appear Satisfied With Hims & Hers Health, Inc.'s (NYSE:HIMS) Prospects As Shares Rocket 49%

Hims & Hers: Turning The Profitability Corner And Returning 28%

Feb 25

Hims & Hers Health: No Clear Moat Besides First Mover Advantage

Jan 23

Hims & Hers Health: Unleashing Macro Momentum - Investing In Growth At A Higher Multiple

Jan 10

Investors Still Waiting For A Pull Back In Hims & Hers Health, Inc. (NYSE:HIMS)

Jan 07
Investors Still Waiting For A Pull Back In Hims & Hers Health, Inc. (NYSE:HIMS)

Hims & Hers Health Q3: The Cheapest Growth Stock Around

Dec 14

Hims & Hers Health: What Would The Author Of 100 Baggers Say?

Nov 30

Hims & Hers: The Most Undervalued Small Cap Stock I See

Nov 08

Hims & Hers: A Promising Company With Resolvable Challenges

Nov 02

Hims & Hers: Specialization Is The Secret To Great Growth

Oct 25

Hims & Hers Health: Can't Get Much Better

Sep 25

The Market Is Wrong On Hims & Hers Health

Sep 18

Hims & Hers: The Current Weakness Creates A Buying Opportunity

Aug 15

Hims & Hers Health: Giving Investors Another Bite At The Apple

Aug 01

Hims & Hers Health, Inc.'s (NYSE:HIMS) Price In Tune With Revenues

Jul 21
Hims & Hers Health, Inc.'s (NYSE:HIMS) Price In Tune With Revenues

Hims & Hers Health: Expect Strong EBITDA Growth As Revenue Growth Remains Strong

Jul 13

Hims & Hers Health: Double-Edged Sword

Jul 02

Hims & Hers: More Transparency Could Help The Stock

Jun 09

Hims & Hers Health (NYSE:HIMS) Is In A Strong Position To Grow Its Business

Apr 19
Hims & Hers Health (NYSE:HIMS) Is In A Strong Position To Grow Its Business

Are Investors Undervaluing Hims & Hers Health, Inc. (NYSE:HIMS) By 41%?

Mar 30
Are Investors Undervaluing Hims & Hers Health, Inc. (NYSE:HIMS) By 41%?

Him & Hers Health Q4 2022 Earnings Preview

Feb 24

Hims & Hers spikes as Jefferies upgrades ahead of 2023 guidance

Feb 09

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Andrew Dudum im Vergleich zu den Einnahmen von Hims & Hers Health verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Mar 31 2024n/an/a

-US$2m

Dec 31 2023US$14mUS$612k

-US$24m

Sep 30 2023n/an/a

-US$36m

Jun 30 2023n/an/a

-US$47m

Mar 31 2023n/an/a

-US$59m

Dec 31 2022US$11mUS$600k

-US$66m

Sep 30 2022n/an/a

-US$86m

Jun 30 2022n/an/a

-US$83m

Mar 31 2022n/an/a

-US$73m

Dec 31 2021US$15mUS$574k

-US$108m

Sep 30 2021n/an/a

-US$82m

Jun 30 2021n/an/a

-US$72m

Mar 31 2021n/an/a

-US$63m

Dec 31 2020US$27mUS$527k

-US$18m

Sep 30 2020n/an/a

-US$25m

Jun 30 2020n/an/a

-US$38m

Mar 31 2020n/an/a

-US$58m

Dec 31 2019US$254kUS$254k

-US$72m

Vergütung im Vergleich zum Markt: AndrewDie Gesamtvergütung ($USD14.40M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD8.44M).

Entschädigung vs. Einkommen: AndrewDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.


Geschäftsführer

Andrew Dudum (35 yo)

7.4yrs

Amtszeit

US$14,401,411

Vergütung

Mr. Andrew Dudum serves as Chairman of the Board and serves as Chief Executive Officer at Hims & Hers Health, Inc. since January 20, 2021. He Co-Founded Hims & Hers Health, Inc. in 2017. He is Co-founded H...


Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Andrew Dudum
Co-Founder7.4yrsUS$14.40m9.1%
$ 433.1m
Yemi Okupe
Chief Financial Officer2.4yrsUS$7.43m0.088%
$ 4.2m
Melissa Baird
Chief Operating Officer3.4yrsUS$6.77m0.27%
$ 13.0m
Soleil Boughton
Chief Legal Officer & Corporate Secretary3.4yrsUS$5.21m0.081%
$ 3.8m
Patrick Carroll
Chief Medical Officer1.5yrsUS$198.26k0.094%
$ 4.5m
Mike Chi
Chief Commercial Officerless than a yearUS$6.71m0.086%
$ 4.1m
Irene Becklund
Senior VP5yrsUS$961.12k0.0014%
$ 64.7k
Khobi Brooklyn
Chief Communications Officerless than a yearkeine Datenkeine Daten
Amee Parekh
Senior Vice President of Human Resources2.3yrskeine Datenkeine Daten
Peter Stahl
Senior VP & Member of Medical Advisory Boardno datakeine Datenkeine Daten
Scott Knoer
Chief Pharmacy & Innovation Officer1.5yrskeine Datenkeine Daten
Daniel Lieberman
Senior Vice President of Mental Health1.3yrskeine Datenkeine Daten

2.3yrs

Durchschnittliche Betriebszugehörigkeit

44yo

Durchschnittliches Alter

Erfahrenes Management: HIMSDas Führungsteam des Unternehmens gilt als erfahren (2.3 Jahre durchschnittliche Betriebszugehörigkeit).


Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Andrew Dudum
Co-Founder3.4yrsUS$14.40m9.1%
$ 433.1m
Patrick Carroll
Chief Medical Officer2.3yrsUS$198.26k0.094%
$ 4.5m
Peter Stahl
Senior VP & Member of Medical Advisory Board2.4yrskeine Datenkeine Daten
Delos Cosgrove
Independent Director3.8yrsUS$194.26k0.025%
$ 1.2m
David Wells
Lead Independent Director3.8yrsUS$227.41k0.087%
$ 4.1m
Andrea Perez Garcia
Independent Director3.3yrsUS$205.51k0.034%
$ 1.6m
Amy Voedisch
Member of Medical Advisory Board2.5yrskeine Datenkeine Daten
Lawrence Jenkins
Member of Medical Advisory Boardno datakeine Datenkeine Daten
Bertha Chen
Member of Medical Advisory Board2.5yrskeine Datenkeine Daten
Denise Asafu-Adjei
Member of Medical Advisory Board2.5yrskeine Datenkeine Daten
Stanton Honig
Member of Medical Advisory Board2.5yrskeine Datenkeine Daten
Stanley Althof
Member of Medical Advisory Board2.5yrskeine Datenkeine Daten

2.5yrs

Durchschnittliche Betriebszugehörigkeit

53yo

Durchschnittliches Alter

Erfahrener Vorstand: HIMSDie Vorstandsmitglieder gelten nicht als erfahren ( 2.5 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.